Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Ovarian Neoplasms 1Neoplasm Metastasis 1Male Urogenital Diseases 1Genital Diseases, Male 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × gedatolisib × Clear all
NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Celcuity Inc

Phase 3 Recruiting
1,180 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡